What are JAK1 inhibitor drugs?

JAK1 inhibitor drugs are pharmacologic agents that share a common mechanism (typically targeting JAK1 (Janus kinase 1)). 1 are currently marketed, with 3 more in clinical development.

What are the marketed JAK1 inhibitor drugs?

Marketed JAK1 inhibitor drugs include Placebo Upadacitinib.

JAK1 inhibitor

1 marketed 1 in Phase 3 2 in Phase 2

This page covers all JAK1 inhibitor drugs tracked by Drug Landscape: marketed products and active clinical-stage compounds, targeting JAK1 (Janus kinase 1), JAK1.

Targets

JAK1 (Janus kinase 1) · JAK1

Marketed (1)

Placebo Upadacitinib · AbbVie · Immunology
Upadacitinib is a JAK1-selective inhibitor that suppresses inflammatory signaling pathways by blocking Janus kinase 1.

Phase 3 pipeline (1)

OPA-15406 · Otsuka Pharmaceutical Development & Commercialization, Inc. · Dermatology / Immunology
OPA-15406 is a selective JAK1 inhibitor that reduces inflammatory signaling to treat immune-mediated skin diseases.

Phase 2 pipeline (2)

ARQ-151 cream 0.05% · Arcutis Biotherapeutics, Inc. · Dermatology
ARQ-151 is a selective Janus kinase 1 (JAK1) inhibitor that modulates cytokine signaling involved in inflammatory responses.
ABT-494 · AbbVie · Immunology
ABT-494 is a JAK1 inhibitor that selectively blocks Janus kinase 1 signaling to reduce inflammatory cytokine production and immune cell activation.